Prelude Therapeutics (PRLD) Invested Capital (2023 - 2026)
Prelude Therapeutics' Invested Capital history spans 4 years, with the latest figure at $60.2 million for Q1 2026.
- On a quarterly basis, Invested Capital fell 41.67% to $60.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $60.2 million, a 41.67% decrease, with the full-year FY2025 number at $68.6 million, down 47.79% from a year prior.
- Invested Capital hit $60.2 million in Q1 2026 for Prelude Therapeutics, down from $68.6 million in the prior quarter.
- Over the last five years, Invested Capital for PRLD hit a ceiling of $237.1 million in Q4 2023 and a floor of $58.5 million in Q3 2025.
- Historically, Invested Capital has averaged $128.4 million across 4 years, with a median of $117.3 million in 2024.
- Biggest five-year swings in Invested Capital: crashed 62.58% in 2025 and later plummeted 41.67% in 2026.
- Tracing PRLD's Invested Capital over 4 years: stood at $237.1 million in 2023, then plummeted by 44.55% to $131.5 million in 2024, then crashed by 47.79% to $68.6 million in 2025, then dropped by 12.32% to $60.2 million in 2026.
- Business Quant data shows Invested Capital for PRLD at $60.2 million in Q1 2026, $68.6 million in Q4 2025, and $58.5 million in Q3 2025.